Resolve Biosciences is applying the power of Molecular Cartography™ to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company’s proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue.
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid …
RVAC Medicines is an mRNA biopharmaceutical company founded in 2021 and headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology platform and strategic partnerships, the company is building a pipeline of innovative mRNA vaccine and therapeutic candidates to treat various diseases of unmet medical needs for the emerging markets and …
Aspen Neuroscience, Inc. is a biotechnology company focused on personalized (autologous) cell therapies. The company is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs. Aspen combines stem cell …
Tessa Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of cancer immunotherapies.
PEAR Therapeutics, a leader in FDA-cleared prescription digital therapeutics, provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Nuvation Bio, is a stealth biotechnology company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology.
I-Mab is a full-stack biopharmaceutical company equipped to discover and develop best- and first-in-class biologics with global potential to treat cancer and auto-immune diseases.
Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.
© 2021- edbi. All rights reserved.
